Savara (SVRA) Convertible Debt (2016)
Savara (SVRA) reported Convertible Debt of $3.4 million for Q4 2016.
Savara (SVRA) Convertible Debt (2016) Analysis & Trends
Savara (SVRA) has 1 years of Convertible Debt data on file, last reported at $3.4 million in Q4 2016.
- Convertible Debt for Q4 2016 came in at $3.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $3.4 million (changed N/A YoY), and the FY2016 annual result was $3.4 million, changed N/A from the prior year.
- Convertible Debt steadied at $3.4 million in Q4 2016 per SVRA's latest filing.
- Over five years, Convertible Debt peaked at $3.4 million in Q4 2016 and troughed at $3.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 3.45 Mn |